Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cassie Port

Nurse Practitioner West Jordan, UT Nurse Practitioner

NPI 1912671272 CMS profile 11081716

3181 W 9000 S, West Jordan, UT 84088

Open in the dashboard

General payments

$9,389

446 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cassie Port of West Jordan, UT is reported in the CMS Open Payments database as having received $9,389 across 446 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,662 148
2024 General $2,310 109
2023 General $1,527 83
2022 General $1,559 84
2021 General $332 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cassie Port
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Cassie Port were reported at $3,662. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Cassie Port Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $332 $135 $40–$426 $132
2022 $1,559 $152 $48–$470 $149
2023 $1,527 $166 $54–$529 $160
2024 $2,310 $173 $55–$556 $164
2025 $3,662 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Inspire Medical Systems, Inc. $1,403 25 payments
  2. AstraZeneca Pharmaceuticals LP $1,055 58 payments
  3. GlaxoSmithKline, LLC. $728 49 payments
  4. Harmony Biosciences LLC $714 30 payments
  5. Mylan Specialty L.P. $557 27 payments
  6. Insmed, Inc. $474 32 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $427 19 payments
  8. Grifols USA, LLC $392 18 payments
  9. United Therapeutics Corporation $383 23 payments
  10. Axsome Therapeutics, Inc. $367 20 payments
  11. Other $2,889 145 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,651 440 payments
  2. Travel and Lodging $346 2 payments
  3. Education $242 3 payments
  4. Consulting Fee $150 1 payment
Products named General payments · program years 2021–2025
  1. INSPIRE $1,403 25 payments
  2. YUPELRI $778 39 payments
  3. Arikayce $468 30 payments
  4. FASENRA $456 24 payments
  5. TRELEGY ELLIPTA $413 26 payments
  6. Prolastin-C Liquid $377 17 payments
  7. Sunosi $367 20 payments
  8. SPIRIVA RESPIMAT $305 16 payments
  9. NUCALA $300 22 payments
  10. Wakix $272 9 payments
  11. Other $5,469 276 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,650

Median for Nurse Practitioner: 389

Drug cost

$737,320

Median for Nurse Practitioner: $21,885

Branded share of claims

58.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 142 $116,401
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 166 $104,789
Spiriva Respimat Tiotropium Bromide Brand 136 $103,389
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 99 $81,847
Orenitram Er Treprostinil Diolamine Brand 13 $61,192
Ambrisentan Generic 15 $42,558
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 59 $38,172
Symbicort Budesonide/Formoterol Fumarate Brand 107 $35,377
Tadalafil Generic 16 $24,950
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 130 $21,101

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$58,976

Medicare's payments for the services billed

Medicare patients

483

Average age 74

Services billed

871

237 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 41%
Chronic kidney disease 29%
Ischemic heart disease 27%
Depression 27%
COPD 22%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $241
$241 — —
YUPELRI
  • Mylan Specialty L.P. $233
$233 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $173
$173 — —
TEZSPIRE
  • Amgen Inc. $85
  • AstraZeneca Pharmaceuticals LP $67
$152 — —
Prolastin-C Liquid
  • Grifols USA, LLC $137
$137 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record